Models:
Joseph Gordon
joseph-gordon/
ClinicalTrialsElig
0
Downloads: 1
[c09aa8]: / clusters / clustall9k / 291.txt

Download this file

214 lines (213 with data), 23.1 kB 

  1
  2
  3
  4
  5
  6
  7
  8
  9
 10
 11
 12
 13
 14
 15
 16
 17
 18
 19
 20
 21
 22
 23
 24
 25
 26
 27
 28
 29
 30
 31
 32
 33
 34
 35
 36
 37
 38
 39
 40
 41
 42
 43
 44
 45
 46
 47
 48
 49
 50
 51
 52
 53
 54
 55
 56
 57
 58
 59
 60
 61
 62
 63
 64
 65
 66
 67
 68
 69
 70
 71
 72
 73
 74
 75
 76
 77
 78
 79
 80
 81
 82
 83
 84
 85
 86
 87
 88
 89
 90
 91
 92
 93
 94
 95
 96
 97
 98
 99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
Within 14 days of treatment initiation: Hemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment)

Hemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment) (up to 14 days before treatment initiation)

Within 14 days of treatment initiation:\r\nHemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment)

Hemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment)

Within 10 days of treatment initiation: Hemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment)

Hemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment), performed within 10 days of treatment initiation

Hemoglobin >= 9 g/dL or >= 5.6 mmol/L (without transfusion or growth factor support/erythropoietin [EPO] dependency)

Hemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment)

Hemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment)

Within 10 (except as noted) days of planned treatment initiation: Hemoglobin >= 9.0 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin dependency (within 7 days of assessment)

Hemoglobin >= 9 g/dL or >= 5.6 mmol/L, performed within 10 days of treatment initiation, without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment)

Within 14 days of treatment registration: Hemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment)

Hemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment), performed within 14 days of treatment initiation

Hemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment) within 14 days of treatment initiation

Hemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment) (performed within 28 days of treatment initiation)

Hemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment), performed within 28 days of study registration

Performed within 10 business days of treatment initiation with the exception of beta- HCG (72 hours), if applicable: Hemoglobin >= 8 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment).

Performed within 10 days of treatment initiation: Hemoglobin ? 9 g/dL or ? 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment)

Hemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment), should be performed within 10 days of treatment initiation

Hemoglobin >= 8 g/dL without transfusion or erythropoietin (EPO) dependency

Hemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment), performed within 10 days of treatment

Hemoglobin ? 9 g/dL or ? 5.6 mmol/L within 21 days of treatment initiation without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment)

Performed within 10 days of treatment initiation: hemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment)

Hemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment) (performed within 10 days of treatment initiation)

Within 5 days prior to the start of study treatment: Hemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment).

Hemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment)

Hemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment), performed within 14 days of treatment initiation

Hemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment)

To be performed within 14 days of treatment initiation: hemoglobin ? 9 g/dL or ? 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment)

Within 10 days of treatment initiation: Hemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment).

Within 14 days of treatment initiation: Hemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment)

Hemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment).

Obtained =< 14 days prior to registration: Hemoglobin > 9.0 g/dL or >= 5.6 mmol/L without transfusion or (EPO) erythropoietin dependency (within 7 days of assessment)

Within 10 days prior to on-study date: Hemoglobin ? 9 g/dL (or ? 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment)

Hemoglobin >= 9 g/dL without transfusion or erythropoietin (EPO) dependency within 7 days

Within 10 days of treatment initiation: Hemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment)

Within 10 days of treatment initiation: Hemoglobin ? 9 g/dL or ? 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment)

Hemoglobin ? 9 g/dL or ? 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment)

Hemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment) (performed within 10 days of treatment initiation)

Performed within 10 days of treatment initiation: Hemoglobin >= 9 g/dL or >= 5.6 mmol/L\r\n* Patients cannot have received transfusion or erythropoietin (EPO) within 7 days of the hemoglobin (Hgb) lab test

Hemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment)

Hemoglobin >= 8 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment), performed within 10 days of treatment initiation

Obtained =< 28 days prior to registration: Hemoglobin >= 9.0 g/dL without transfusion or erythropoietin (EPO) dependency (=< 7 days prior to assessment)

Performed within 7 days of treatment initiation: Hemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment)

Hemoglobin >= 8 g/dL without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment), performed within 14 days of treatment initiation

Hemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment), performed within 10 days of treatment initiation

Performed within 10 days of treatment initiation: Hemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment)

Hemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment)

Hemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment)

Hemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment)

Hemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment)

Within 10 days of treatment initiation: Hemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment)

Within 14 days of treatment initiation: Hemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment)

Hemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment), performed within 14 days of registration

Performed within 10 days of treatment initiation: Hemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment)

Hemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment)

Hemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment)

Hemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment) (performed within 28 days of registration)

Hemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment)

Hemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment)

Hemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment)

Hemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment) (within 10-15 days of treatment initiation)

Hemoglobin >= 8 g/dL without transfusion or erythropoietin (EPO) dependency within 7 days performed within 7 days of treatment initiation performed within 7 days of treatment initiation

Hemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment), during screening and on cycle 1, day 1

Hemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment) within 14 days of treatment initiation

Hemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 14 days of assessment) (performed within 10 days of treatment initiation)

Hemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment)

Hemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment)

Within 10 days of treatment initiation: Hemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment)

Hemoglobin: >= 9 g/dL or 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment)

Completed within 10 days of SBRT treatment initiation: Hemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment)

Hemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment)

Hemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment)

Hemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency\r\n(within 7 days of assessment)

Hemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment)

Hemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment)

Hemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment)

Within 10 days of treatment initiation: Hemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment)

Hemoglobin >= 8 g/dL without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment), performed within 10 days of treatment initiation

Hemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment)

Hemoglobin >= 8 g/dL without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment)

Hemoglobin ? 9 g/dL OR ? 8 g/dL if anemia due to iBCL, without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment)

Hemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment), should be performed within 10 days of treatment initiation

Hemoglobin >= 7 g/dL or >= 5.6 mmol/L with transfusion or erythropoietin (EPO) dependency

REGISTRATION TO TREATMENT (STEP 1): Hemoglobin (Hgb) >= 9.0 g/dL OR >= 5.6 mmol/L without transfusion of erythropoietin (EPO) dependency, within 14 days prior to first dose of pembrolizumab

REGISTRATION TO TREATMENT (STEP 2): Hgb >= 9.0 g/dL OR >= 5.6 mmol/L without transfusion of EPO dependency, within 14 days prior to first dose of pembrolizumab

Within 10 days of treatment initiation: hemoglobin >= 9 g/dl without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment)

Hemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment), performed within 28 days of treatment initiation

Within 10 days of treatment initiation: Hemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment)

Hemoglobin (Hgb) > 9 g/dL (without transfusion or erythropoietin [EPO] dependency within 7 days of assessment)

Hemoglobin >= 9.0 g/dL (5.6 mmol/L or 90 g/L) without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment) obtained =< 28 days prior to registration

Hemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment) (performed within 10 days of treatment initiation)

Hemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment)

Hemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment)

Hemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment)

Hemoglobin >= 8 g/dL without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment)

Hemoglobin >= 8 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment)

Hemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment) (within 14 days prior to day 1 of protocol therapy)

Hemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment) (performed within 10 days of treatment initiation)

Hemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment), performed within 10 days of treatment initiation

Hemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency

Hemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment)

Hemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment), should be performed within 28 days of treatment initiation, unless otherwise indicated

Hemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment)

Hemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment)

Hemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment)

Hemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment) within 7 days of treatment initiation

Hemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment)

Hemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment) (performed within 10 days of treatment initiation)

Hemoglobin (Hgb) >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment of Hgb), obtained within 14 days prior to C11-AMT PET scan

Hemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment)

Within 14 days of treatment initiation: Hemoglobin >= 9 g/dL OR >= 5.6 mmol/L

Hemoglobin >= 9 g/dL or >= 5.6 mmol/L

Within 21 days of treatment initiation:\r\nHemoglobin >= 9 g/dL or >= 5.6 mmol/L

Hemoglobin >= 8 g/dL (5.0 mmol/L)

Hemoglobin >= 9 g/dL (5.6 mmol/L)

Hemoglobin ? 8.0 g/dL (4.96 mmol/L)

SAFETY RUN-IN: Within 10 days of registration: Hemoglobin >= 9 g/dL or >= 5.6 mmol/L

RANDOMIZED PHASE II CLINICAL TRIAL: Within 10 days of registration: Hemoglobin >= 9 g/dL or >= 5.6 mmol/L

Hemoglobin ? 9 g/dL or ? 5.6 mmol/L

Hemoglobin >= 9 g/dL or >= 5.6 mmol/L.

Hemoglobin >= 9.0 g/dL (5.58 mmol/L)

Hemoglobin >= 8.5 g/dL or >= 5.6 mmol/L

Hemoglobin >= 9.0 g/dL (1.4 mmol/L)

Hemoglobin >= 9 g/dL or >= 5.6 mmol/L

At time of registration and within 4 weeks prior to initiating on-protocol treatment: Hemoglobin >= 9 g/dL or >= 5.6 mmol/L

Within 10 days prior to the start of study treatment: Hemoglobin >= 9.0 g/dL or >= 5.6 mmol/L

Hemoglobin >= 8 g/dL or >= 5.0 mmol/L within 21 days of treatment initiation

Hemoglobin >= 9 g/dL or >= 5.6 mmol/L, performed within 28 days of treatment initiation

Hemoglobin 8.0 g/dL (5.0 mmol/L)

Within 7 days of registration: Hemoglobin >= 9.0 g/gL or >= 5.6 mmol/L, without recent transfusion

Hemoglobin ?9.0 g/dL (?5.6 mmol/L);.

Hemoglobin >= 7 g/dL or >= 5.6 mmol/L within 14 days prior to registration

Hemoglobin >= 9 g/dL (5.58 mmol/L)

Hemoglobin >= 9 g/dL or >= 5.6 mmol/L

Hemoglobin >= 9 g/dL or >= 5.6 mmol/L

Performed 28 days prior to study registration up to the first dose of study drug: hemoglobin >= 9 g/dL or >= 5.6 mmol/L

Performed within 14 days (+3 working days) of treatment initiation: Hemoglobin >= 9 g/dL or >= 5.6 mmol/L

Hemoglobin >= 9 g/dL or >= 5.6 mmol/L

Performed within 14 days of treatment initiation: Hemoglobin >= 8 g/dL or >= 5.6 mmol/L

Hemoglobin >= 9.0 g/dL or >= 5.6 mmol/L

Hemoglobin >= 9 g/dL or >= 5.6 mmol/L except in cases of marrow infiltration by lymphoma

Hemoglobin >= 9 g/dL (5.58 mmol/L)

Hemoglobin >= 9 g/dL or >= 5.6 mmol/L

Hemoglobin < 9 g/dL (5.6 mmol/L)

Hemoglobin >= 9 g/dL or >= 5.6 mmol/L

Hemoglobin >= 9.0 g/dL (1.4 mmol/L)

Performed within 28 days prior to study registration up to the first dose of study drug: Hemoglobin >= 9 g/dL or >= 5.6 mmol/L

Hemoglobin >= 9 g/dL or >= 5.6 mmol/L

Hemoglobin >= 9 g/dL or >= 5.6 mmol/L

Hemoglobin >= 9 g/dL or >= 5.6 mmol/L, performed within 10 days of treatment initiation

Hemoglobin >= 9 g/dL or >= 5.6 mmol/L

Performed within 10 days of treatment initiation; hemoglobin ? 9 g/dL or ? 5.6 mmol/L

Hemoglobin >= 9 g/dL or >= 5.6 mmol/L

Magnesium < 1.4 mg/dl (< 0.4 mmol/L) or > 3 mg/dl (> 1.23 mmol/L) despite intervention to normalize levels

Hemoglobin >= 9 g/dL or >= 5.6 mmol/L

Hemoglobin >= 9 g/dL or >= 5.6 mmol/L

Hemoglobin >= 9 g/dL or >= 5.6 mmol/L

Hemoglobin >= 9 g/dL or >= 5.6 mmol/L

Hemoglobin >= 9 g/dL (5.6 mmol/L); subjects may not have had a transfusion within 7 days of screening assessment

Hemoglobin >= 9 g/dL or >= 5.6 mmol/L

Hemoglobin ? 9 g/dL or ? 5.6 mmol/L within 7 days of treatment initiation

Hemoglobin ? 9g/dL or ? 5.6 mmol/L

Hemoglobin >= 8 g/dL or >= 4.96 mmol/L

Magnesium < 0.9 mg/dl (< 0.4 mmol/L) or > 3 mg/dl (> 1.23 mmol/L) despite intervention to normalize levels

Magnesium < 0.9 mg/dl (< 0.4 mmol/L) or > 3 mg/dl (> 1.23 mmol/L) despite intervention to normalize levels

Hemoglobin >= 9 g/dL or >= 5.6 mmol/L

Hemoglobin >= 9 g/dL or >= 5.6 mmol/L

Hemoglobin >= 9 g/dL OR >= 5.6 mmol/L

Within 30 days prior to treatment initiation: Hemoglobin >= 9 g/dL or >= 5.6 mmol/L; transfusions permitted

Hemoglobin >= 9.0 g/dL or >= 5.6 mmol/L

Hemoglobin >= 9 g/dL (5.58 mmol/L)

Hemoglobin greater than 8.0 g/dL (= 80 g/L or 4.9 mmol/L)

Hemoglobin ?9 g/dL or ?5.6 mmol/L

Hemoglobin >=9 g/dL or >= 5.6 mmol/L

Hemoglobin >= 9 g/dL or >= 5.6 mmol/L

Hemoglobin ?9 g/dL or ?5.6 mmol/L- without qualifications

Hemoglobin >= 9 g/dL or >= 5.6 mmol/L

Hemoglobin >= 9 g/dL or >= 5.6 mmol/L

Hemoglobin ? 8.0 g/dL (4.96 mmol/L)

Hemoglobin < 8.5 g/dL (< 5.3 mmol/L)

Hemoglobin >= 9 g/dL or >= 5.6 mmol/L

Hemoglobin >= 9 g/dL or >= 5.6 mmol/L

Hemoglobin >= 9 g/dL or >= 5.6 mmol/L

Hemoglobin >= 9 g/dL or >= 5.6 mmol/L, performed within 14 days prior to registration

Within 14 days of treatment initiation: Hemoglobin >= 9 g/dL or >= 5.6 mmol/L

Performed within 28 days of radiation therapy: Hemoglobin >= 9 g/dL or >= 5.6 mmol/L

Hemoglobin >= 9 g/dL or >= 5.6 mmol/L, performed within 28 days of treatment initiation

Hemoglobin >= 9 g/dL (or >= 5.6 mmol/L)

Hemoglobin >= 9 g/dL OR >= 5.6 mmol/L (labs should be performed within 14 days of treatment initiation)

Hemoglobin >= 9 g/dL (5.6 mmol/L) (tested within 14 days prior to registration)\r\n* Subjects may not have had a transfusion within 7 days of screening assessment

Hemoglobin >= 9 g/dL (5.6 mmol/L); subjects may not have had a transfusion within 7 days of screening assessment

Hemoglobin >= 9 g/dL (5.6 mmol/L); subjects may not have had a transfusion within 7 days of screening assessment

Hemoglobin >= 9 g/dL (5.6 mmol/L); subjects may not have had a transfusion within 7 days of screening assessment

Hemoglobin >= 9 g/dL (5.6 mmol/L); subjects may not have had a transfusion within 7 days of screening assessment

Hemoglobin >= 9 g/dL (5.6 mmol/L)

Hemoglobin ?8.0 g/dL (?4.96 mmol/L)

Hemoglobin >= 9 g/dL or >= 5.6 mmol/L

Hemoglobin ? 9 g/L (?5.6 mmol/L).

Hemoglobin ? 8.0 g/dL (4.96 mmol/L)

Performed within 10 days of treatment initiation: Hemoglobin >= 9 g/dL OR >= 5.6 mmol/L

Bone Marrow: Absolute neutrophil count ANC ? 1,500/mm3 (1.5 × 109/L); Platelets ? 100,000/mm3 (100 × 109/L); Hemoglobin ? 9.5 g/dL (1.4 mmol/L). Subjects with hemoglobin ? 9.5 g/dL (1.4 mmol/L) following transfusion are eligible;

Hemoglobin ? 9 g/dL or ? 5.6 mmol/L

Hemoglobin >= 10 g/dL (6.2 mmol/L)

Hemoglobin < 9 g/dL (5.6 mmol/L)

Performed within 10 days of treatment initiation: Hemoglobin >= 9 g/dL or >= 5.6 mmol/L

Hemoglobin (Hgb) >= 9 g/dL or >= 5.6 mmol/L

Hemoglobin >= 9 g/dL or >= 5.6 mmol/L, performed within 10 days of treatment initiation

Hemoglobin >= 9.0 g/dL or >= 5.6 mmol/L

Hemoglobin >= 9 g/dL (5.6 mmol/L) (evaluated within 28 days of randomization); subjects may not have had a transfusion within 7 days of screening assessment

Hemoglobin >= 8.5 g/dL or >= 5.6 mmol/L, performed within 10 days of treatment initiation

Hemoglobin > 5.6 mmol/L (9 g/dL) at the screening visit

Hemoglobin >= 8.5 g/dL or >= 5.6 mmol/L